Cargando…

A review of the clinical experience with CMN-001, a tumor RNA loaded dendritic cell immunotherapy for the treatment of metastatic renal cell carcinoma

Engineering dendritic cells (DCs) to treat cancer is a long sought-after goal for cell-based immunotherapies. In this review, we focus on the experience with CMN-001, formally AGS-003, a DC-based immunotherapy, employing autologous DC electroporated with autologous tumor RNA to treat subjects with m...

Descripción completa

Detalles Bibliográficos
Autores principales:	DeBenedette, Mark, Gamble, Alicia, Norris, Marcus, Horvatinovich, Joe, Nicolette, Charles A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2023
Materias:	Immunotherapy - Cancer
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10332239/ https://www.ncbi.nlm.nih.gov/pubmed/37387210 http://dx.doi.org/10.1080/21645515.2023.2220629

Ejemplares similares

Multi-functional cytotoxic T cell expansion correlates with overall survival after administration of autologous dendritic cell immunotherapy in renal cell cancer patients
por: DeBenedette, M, et al.
Publicado: (2013)

Autologous dendritic cells loaded with antigens from self-renewing autologous tumor cells as patient-specific therapeutic cancer vaccines
por: Dillman, Robert O., et al.
Publicado: (2023)

Adoptive T Cell Immunotherapy for Cancer
por: Perica, Karlo, et al.
Publicado: (2015)

The emerging landscape of neo/adjuvant immunotherapy in renal cell carcinoma
por: Dibajnia, Pooya, et al.
Publicado: (2023)

Update on combined immunotherapy for the treatment of advanced renal cell carcinoma
por: Gebrael, Georges, et al.
Publicado: (2023)

Bibliometric analysis on the progress of immunotherapy in renal cell carcinoma from 2003-2022
por: Zhu, Haiyan, et al.
Publicado: (2023)

Radiomics to predict immunotherapy efficacy in advanced renal cell carcinoma: A retrospective study
por: Rossi, Ernesto, et al.
Publicado: (2023)

Targeting resistance to radiation-immunotherapy in cold HNSCCs by modulating the Treg-dendritic cell axis
por: Knitz, Michael W, et al.
Publicado: (2021)

IMMU-12. PHASE I/II TRIAL OF IMMUNOTHERAPY WITH FUSIONS OF DENDRITIC CELLS AND TUMOR CELLS FOR RELAPSED OR REFRACTORY BRAIN TUMORS IN CHILDREN AND YOUNG ADULTS
por: Yamaoka, Masayoshi, et al.
Publicado: (2020)

Global research trends on immunotherapy in cancer: A bibliometric analysis
por: Yao, Zhichao, et al.
Publicado: (2023)

Visual analysis of global research on immunotherapy for gastric cancer: A literature mining from 2012 to 2022
por: Chen, Yizhen, et al.
Publicado: (2023)

Global research trends on B7-H3 for cancer immunotherapy: A bibliometric analysis (2012-2022)
por: Huang, Xiaojuan, et al.
Publicado: (2023)

IMMU-22. PHASE IB IMMUNOTHERAPY CLINICAL TRIAL WITH THE USE OF AUTOLOGOUS DENDRITIC CELLS PULSED WITH AN ALLOGENIC TUMORAL CELL LINES LYSATE IN PATIENTS WITH NEWLY DIAGNOSED DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)
por: Madrid, Andres Morales La, et al.
Publicado: (2020)

Recurrent pleural effusion as a rare manifestation after prolonged PD1 inhibitor (camrelizumab)-based immunotherapy: A case report
por: Xie, Xiao-Hong, et al.
Publicado: (2023)

Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma
por: Saberian, Chantal, et al.
Publicado: (2021)

Immune cell and tumor cell-derived CXCL10 is indicative of immunotherapy response in metastatic melanoma
por: Reschke, Robin, et al.
Publicado: (2021)

Identification of key immune cell-related genes involved in tumorigenesis and prognosis of cervical squamous cell carcinoma
por: Yan, Chunxiao, et al.
Publicado: (2023)

First-line ICIs in renal cell carcinoma
por: Fiorentino, Vincenzo, et al.
Publicado: (2023)

Adjuvant dendritic cell-based immunotherapy after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with malignant peritoneal mesothelioma: a phase II clinical trial
por: Dietz, Michelle V, et al.
Publicado: (2023)

Advances in immunotherapy for cervical cancer
por: Grau-Bejar, Juan Francisco, et al.
Publicado: (2023)

Effect of cyclo-oxygenase inhibitor use during checkpoint blockade immunotherapy in patients with metastatic melanoma and non-small cell lung cancer
por: Wang, Shang-Jui, et al.
Publicado: (2020)

Evaluation of RNA Amplification Methods to Improve DC Immunotherapy Antigen Presentation and Immune Response
por: Slagter-Jäger, Jacoba G, et al.
Publicado: (2013)

Immune checkpoint inhibitors in non-conventional histologies of renal-cell carcinoma
por: Bersanelli, Melissa, et al.
Publicado: (2023)

Classification of the tumor immune microenvironment and associations with outcomes in patients with metastatic melanoma treated with immunotherapies
por: Adegoke, Nurudeen A, et al.
Publicado: (2023)

Melanoma stem cell vaccine induces effective tumor immunity against melanoma
por: Yin, Qiliang, et al.
Publicado: (2023)

Principles and current clinical landscape of NK cell engaging bispecific antibody against cancer
por: Huan, Tian, et al.
Publicado: (2023)

Assessing the impact of AGS-004, a dendritic cell-based immunotherapy, and vorinostat on persistent HIV-1 Infection
por: Gay, Cynthia L., et al.
Publicado: (2020)

Immunotherapy as a treatment strategy in advanced stage and recurrent endometrial cancer: review of current phase III immunotherapy clinical trials
por: Eskander, Ramez N., et al.
Publicado: (2021)

Immune checkpoint inhibitors as first-line therapy for non-small cell lung cancer: A systematic evaluation and meta-analysis
por: Lu, Yu, et al.
Publicado: (2023)

Effects of combining immune checkpoint inhibitors and anti-angiogenic agents on bone metastasis in non-small cell lung cancer patients
por: Xie, Xiaohong, et al.
Publicado: (2023)

IMMU-15. PROTEOGENOMIC DISCOVERY OF NOVEL TUMOR PEPTIDES AS NEOANTIGENS FOR PERSONALIZED T CELL IMMUNOTHERAPY IN MEDULLOBLASTOMA
por: Rivero-Hinojosa, Samuel, et al.
Publicado: (2020)

On-treatment immune prognostic score for patients with relapsed and/or metastatic head and neck squamous cell carcinoma treated with immunotherapy
por: Nenclares, Pablo, et al.
Publicado: (2021)

IMMU-06. T-CELL IMMUNOTHERAPY FOR PEDIATRIC BRAIN TUMORS: DIVERSITY IN CELL SURFACE ANTIGEN AND HLA EXPRESSION NECESSITATES A MULTI-PRONGED APPROACH
por: Houke, Haley, et al.
Publicado: (2020)

Clinical and immunologic impact of short-course enzalutamide alone and with immunotherapy in non-metastatic castration sensitive prostate cancer
por: Madan, Ravi A, et al.
Publicado: (2021)

Naive T cells inhibit the outgrowth of intractable antigen-activated memory T cells: implications for T-cell immunotherapy
por: Sharma, Sandhya, et al.
Publicado: (2023)

IMMU-16. INTRA-TUMOURAL IL-12 DELIVERY ENABLES CAR T-CELL IMMUNOTHERAPY FOR HIGH-GRADE GLIOMA
por: Agliardi, Giulia, et al.
Publicado: (2020)

A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti–PD-1 antibody, in patients with advanced solid tumors
por: Naing, Aung, et al.
Publicado: (2020)

Correlates of clinical benefit from immunotherapy and targeted therapy in metastatic renal cell carcinoma: comprehensive genomic and transcriptomic analysis
por: Dizman, Nazli, et al.
Publicado: (2020)

Non-thermal histotripsy tumor ablation promotes abscopal immune responses that enhance cancer immunotherapy
por: Qu, Shibin, et al.
Publicado: (2020)

Clinical activity of PD-1 inhibition in the treatment of locally advanced or metastatic basal cell carcinoma
por: In, Gino Kim, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ubnuq49m9j5qpb8mc3bmoc7r8r